A step forward for LRRK2 inhibitors in Parkinson's disease
- PMID: 35675432
- DOI: 10.1126/scitranslmed.abq7374
A step forward for LRRK2 inhibitors in Parkinson's disease
Abstract
A phase 1 clinical trial for kinase inhibitors targeting LRRK2 provides the foundation for testing the efficacy of LRRK2 kinase inhibitors in Parkinson's disease.
Comment on
-
Preclinical and clinical evaluation of the LRRK2 inhibitor DNL201 for Parkinson's disease.Sci Transl Med. 2022 Jun 8;14(648):eabj2658. doi: 10.1126/scitranslmed.abj2658. Epub 2022 Jun 8. Sci Transl Med. 2022. PMID: 35675433
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
